Edaravone
Brand names: Radicava
Edaravone is a free-radical scavenger used to slow functional decline in amyotrophic lateral sclerosis (motor neurone disease) in selected patients.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It acts as an antioxidant that scavenges reactive oxygen species, thereby reducing oxidative stress thought to contribute to motor neurone injury.
Prescribing in practice
- Hypersensitivity and anaphylactic reactions can occur, so administer with appropriate monitoring and resuscitation provision available for intravenous use.
- Sodium bisulfite-containing formulations may provoke reactions in susceptible individuals, including those with sulfite sensitivity.
- Treatment is given in intermittent cycles, and an oral formulation is available in some settings as an alternative to the intravenous route.
Monitoring
Monitor for hypersensitivity reactions during and after administration and assess functional status to judge ongoing benefit.
Counselling the patient
- Report any rash, breathlessness, swelling or itching during or after treatment.
- Treatment is given in repeated cycles; keep to the scheduled appointments.
- Discuss any history of sulfite sensitivity with the team.
Evidence & guidelines
A randomised placebo-controlled trial demonstrated a reduction in the rate of functional decline in a defined ALS subgroup.
Reference: MCI186 ALS19 trial Lancet Neurology 2017; 16(7):505-512; MHRA 2023; FDA label; EFNS ALS Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- CAHP Cardiac Arrest Hospital Prognosis Score · Cardiac Arrest
- Glasgow Coma Scale · Neurological
- Cushing Syndrome Probability Score · Adrenal Disorders
- Acromegaly Diagnosis Score (SAGIT) · Pituitary Disorders
- Adrenal Crisis Risk Score · Adrenal Disorders
- Pheochromocytoma Clinical Probability (10% Rule) · Adrenal Disorders
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS